We provide you with 20 years of free, institutional-grade data for IBRX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IBRX. Explore the full financial landscape of IBRX stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Simon Barry J. | Sale | -5,453 | $3.42 | $18,649 | 2025-02-25 |
| Simon Barry J. | Derivatives Exercise | 15,243 | 2025-02-25 | ||
| LAUER REGAN J | Sale | -1,669 | $3.42 | $5,708 | 2025-02-25 |
| LAUER REGAN J | Derivatives Exercise | 4,065 | 2025-02-25 | ||
| Adcock Richard | Sale | -78,167 | $3.42 | $267,331 | 2025-02-25 |
| Adcock Richard | Derivatives Exercise | 152,439 | 2025-02-25 | ||
| Sachs David C. | Sale | -15,860 | $3.42 | $54,241 | 2025-02-25 |
| Sachs David C. | Derivatives Exercise | 40,650 | 2025-02-25 | ||
| SOON-SHIONG PATRICK | Sale | -42,071 | $3.42 | $143,883 | 2025-02-25 |
| SOON-SHIONG PATRICK | Derivatives Exercise | 114,329 | 2025-02-25 | ||
| Simon Barry J. | Derivatives Exercise | 110,020 | 2025-01-24 | ||
| Adcock Richard | Sale | -17,475 | $2.56 | $44,736 | 2025-01-03 |
| Adcock Richard | Derivatives Exercise | 34,483 | 2025-01-03 | ||
| Sachs David C. | Sale | -15,405 | $2.56 | $39,437 | 2025-01-03 |
| Sachs David C. | Derivatives Exercise | 30,397 | 2025-01-03 | ||
| LAUER REGAN J | Sale | -7,503 | $2.87 | $21,534 | 2024-12-16 |
| LAUER REGAN J | Derivatives Exercise | 21,031 | 2024-12-16 | ||
| Adcock Richard | Sale | -43,165 | $4.04 | $174,387 | 2024-02-06 |
| Adcock Richard | Derivatives Exercise | 83,334 | 2024-02-06 | ||
| Sachs David C. | Sale | -26,835 | $3.36 | $90,166 | 2024-02-02 |
| Sachs David C. | Derivatives Exercise | 70,745 | 2024-02-02 | ||
| Simon Barry J. | Sale | -22,094 | $3.36 | $74,236 | 2024-02-02 |
| Simon Barry J. | Derivatives Exercise | 57,200 | 2024-02-02 | ||
| LAUER REGAN J | Sale | -13,470 | $3.36 | $45,259 | 2024-02-02 |
| LAUER REGAN J | Derivatives Exercise | 32,872 | 2024-02-02 | ||
| Sachs David C. | Sale | -10,511 | $5.02 | $52,765 | 2024-01-03 |
| Sachs David C. | Derivatives Exercise | 30,397 | 2024-01-03 | ||
| Adcock Richard | Sale | -17,096 | $5.02 | $85,822 | 2024-01-03 |
| Adcock Richard | Derivatives Exercise | 34,483 | 2024-01-03 | ||
| LAUER REGAN J | Derivatives Exercise | 21,030 | 2023-12-19 | ||
| LAUER REGAN J | Derivatives Exercise | 32,872 | 2023-09-06 | ||
| Sachs David C. | Derivatives Exercise | 70,744 | 2023-09-06 | ||
| Simon Barry J. | Derivatives Exercise | 57,199 | 2023-09-06 | ||
| LAUER REGAN J | Derivatives Exercise | 21,030 | 2023-06-16 | ||
| BLASZYK MICHAEL D | Open Market Purchase | 71,915 | $2.72 | 2023-06-05 | |
| Brennan John Owen | Open Market Purchase | 25,000 | $2.74 | 2023-06-05 | |
| Clark Wesley | Open Market Purchase | 7,000 | $2.91 | 2023-06-05 | |
| Adcock Richard | Sale | -42,192 | $4.33 | $182,691 | 2023-02-07 |
| Adcock Richard | Derivatives Exercise | 83,333 | 2023-02-07 | ||
| Adcock Richard | Sale | -4,273 | $5.07 | $21,664 | 2023-01-04 |
| Adcock Richard | Derivatives Exercise | 8,620 | 2023-01-04 | ||
| Sachs David C. | Derivatives Exercise | 7,598 | 2023-01-04 | ||
| Adcock Richard | Sale | -29,415 | $5.39 | $158,547 | 2022-02-08 |
| Adcock Richard | Derivatives Exercise | 83,333 | 2022-02-08 | ||
| Sachs David C. | Derivatives Exercise | 17,242 | 2021-12-13 | ||
| Adcock Richard | Open Market Purchase | 1,930 | $9 | 2021-10-08 | |
| Sachs David C. | Derivatives Exercise | 7,598 | 2021-09-13 | ||
| Adcock Richard | Sale | -4,273 | $9.95 | $42,516 | 2021-09-13 |
| Adcock Richard | Derivatives Exercise | 8,620 | 2021-09-13 | ||
| Cohen Cheryl | Sale | -24,777 | $10 | $247,889 | 2021-08-24 |
| Cohen Cheryl | Sale | -45,531 | $10.12 | $460,956 | 2021-08-19 |
The information provided in this report about IBRX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
ImmunityBio, Inc(NASDAQ:IBRX) 
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy. It develops an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), checkpoint inhibitors, m...
Share this website to your friends